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Abstract
Genetic variants in intron 1 of the fat mass– and obesity-associated (FTO) gene have been consistently associated with body
mass index (BMI) in Europeans. However, follow-up studies in African Americans (AA) have shown no support for some of
the most consistently BMI–associated FTO index single nucleotide polymorphisms (SNPs). This is most likely explained by
different race-specific linkage disequilibrium (LD) patterns and lower correlation overall in AA, which provides the
opportunity to fine-map this region and narrow in on the functional variant. To comprehensively explore the 16q12.2/FTO
locus and to search for second independent signals in the broader region, we fine-mapped a 646–kb region, encompassing
the large FTO gene and the flanking gene RPGRIP1L by investigating a total of 3,756 variants (1,529 genotyped and 2,227
imputed variants) in 20,488 AAs across five studies. We observed associations between BMI and variants in the known FTO
intron 1 locus: the SNP with the most significant p-value, rs56137030 (8.361026) had not been highlighted in previous
studies. While rs56137030was correlated at r2.0.5 with 103 SNPs in Europeans (including the GWAS index SNPs), this
number was reduced to 28 SNPs in AA. Among rs56137030 and the 28 correlated SNPs, six were located within candidate
intronic regulatory elements, including rs1421085, for which we predicted allele-specific binding affinity for the transcription
factor CUX1, which has recently been implicated in the regulation of FTO. We did not find strong evidence for a second
independent signal in the broader region. In summary, this large fine-mapping study in AA has substantially reduced the
number of common alleles that are likely to be functional candidates of the known FTO locus. Importantly our study
demonstrated that comprehensive fine-mapping in AA provides a powerful approach to narrow in on the functional
candidate(s) underlying the initial GWAS findings in European populations.
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Introduction
The association between variants in the fat mass and obesity
associated (FTO) gene on chromosome 16q12.2 and body mass
index (BMI) is well-established in populations of European
descent. Genome-wide association studies (GWAS) and subse-
quent replication studies have identified several strongly correlated
single nucleotide polymorphisms (SNPs) located in intron 1 of FTO
associated with increased BMI and increased risk of obesity [1–
13]. With an observed effect size of 0.35 kg/m2 (0.1 z-score units
of BMI) per risk allele, the FTO locus has a substantially stronger
effect on BMI than any other identified common locus [14]. While
this impact on BMI may seem small, it has a potential public
health bearing, as even a 1 unit increase in BMI results in an
estimated 8% increase in coronary heart disease [15], and excess
weight in midlife is associated with increased mortality [16]. Thus,
a seemingly small increase in BMI can have a marked impact,
particularly in countries with an increasing burden of excess
weight, such as the US, where an estimated 68% of adults were
overweight or obese in 2008 [17].
Studies in non-European populations have had varied success in
replicating the findings at the FTO locus. While several studies
showed an association between FTO SNPs and obesity-related
phenotypes in Hispanic [5,6,18,19] and Asian populations [20–
26], studies of African or African American (AA) subjects showed
limited support for some of the most consistent FTO GWAS
findings initially identified in subjects of European descent
[2,5,6,14,18,19,27–32]. This lack of generalization in AA may
be attributable to the lower levels of linkage disequilibrium (LD)
with the underlying functional variant(s) at the 16q12.2/FTO
locus, as compared with European Americans (EAs). SNPs
discovered in GWAS (i.e. ‘‘index SNPs’’) are often not the
functional variants; however, they do tag genomic regions
harboring strongly correlated variants, one or more of which are
the potentially functional variant(s). Because different ancestral
populations differ in their LD patterns, an index SNP discovered
in one ancestral group (e.g. EA) may or may not be strongly
correlated with the functional variant(s) in a different ancestral
group (e.g. AA). Thus, the index SNP may not show evidence for
replication in AAs; however, other SNPs in the region may be in
high LD with the functional variant(s), and, hence, measuring
these SNPs may further characterize associations within the
genomic region. Therefore, a full exploration of potential
replication/generalizability of GWAS findings in other ancestral
groups requires investigating not only at the index SNP(s), but also
examining, if possible, all variants of the region tagged by the
index SNP(s). African populations are particularly suited for these
studies because the LD pattern between SNPs tends to be
substantially weaker than in other ancestral groups, as has been
demonstrated for the FTO gene [30]. This process can reduce the
number of potential functional variants for follow-up molecular
investigation [33]. Given that functional studies can be labor- and
cost-intensive, narrowing the associated region is an important
step toward elucidating the underlying molecular mechanism.
While molecular evaluation of the 16q12.2/FTO locus provides
some promising leads [34], the putative functional variant(s) in this
locus remain under investigation, and fine-mapping studies have
been limited with respect to the number of tested variants, sample
sizes and inclusion of non-EA populations. Fine-mapping studies,
particularly when conducted within a broader region, may also
identify additional independent signal(s) implicating multiple
functional variants in the region. To better understand the
relationship of genetic variation at this locus and BMI in AAs, we
comprehensively assessed the association of BMI with variants in
the 16q12.2/FTO region and flanking gene RPGRIP1L in over
20,000 AA samples from the Population Architecture using
Genetics and Epidemiology (PAGE) consortium. We used the
Metabochip as genotyping platform [35], which included all
suitable SNPs discovered in the 1000 Genomes Project Pilot 1 for
the 16q12.2/FTO region and led to successfully genotyping of over
Author Summary
Genetic variants within the fat mass– and obesity-associated
(FTO) gene are associated with increased risk of obesity. To
better understand which specific genetic variant(s) in this
genetic region is associated with obesity risk, we attempt
to genotype or impute all known genetic variants in the
region and test for association with body mass index as a
measurement of obesity in over 20,000 African Americans.
We identified 29 potential candidate variants, of which one
variant (rs1421085) is a particularly interesting candidate
for future functional follow-up studies. Our example shows
the powerful approach of studying a large African
American population, substantially reducing the number
of possible functional variants compared with European
descent populations.
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1,500 SNPs. This together with imputation into the updated 1000
Genomes Project allowed us to densely fine-mapping this region. In
addition, we performed a detailed bioinformatic analysis to propose
candidate polymorphisms for follow-up functional evaluation.
Results
The age of the 20,488 participants ranged from 20 to 85 years
with an average age of 58.5 years across the cohorts (Table 1). The
fraction of men included in each cohort varied from 0% to 43%.
In all studies that included both genders, men had on average a
lower BMI than the women. Participants in the Hypertensive
Genetic Epidemiology Network (HyperGEN) had the highest BMI
while participants in the Multiethnic Cohort (MEC) had the lowest
BMI. The obesity rate (defined as BMI$30 kg/m2) across the
studies was 46% ranging from 31% to 58%.
The targeted 16q12.2/FTO fine-mapping region spans 646 kb
from 53,539,509 to 54,185,773 (build 37) on the long arm of
chromosome 16 (16q12.2), including the large FTO gene (411 kb)
as well as 198 kb downstream of FTO, which includes the
RPGRIP1L gene and 37 kb upstream of FTO (Figure 1). On
average, we successfully genotyped or imputed one SNP per
172 bp ( = 646,264 bp/3,756 SNPs). The allele frequency distri-
bution of the 3,756 SNPs in this region is shown in Table 2. In
contrast to GWAS platforms, a large fraction of SNPs have allele
frequencies ,5% (52.5%), including 16.7% with allele frequency
,1%. Twenty-one SNPs are within the exons of FTO and
RPGRIP1L, of which 7 are synonymous and 14 are missense (2
synonymous and 4 missense are located in FTO).
The most significant SNPs in the 16q12.2/FTO fine-mapping
region was rs56137030 (p-value 8.361026), which showed no
evidence for heterogeneity (p = 0.13; Table 3). Each A allele of this
variant (allele frequency = 0.12) increased BMI by 1.35% (95%
confidence interval (0.76%–1.95%). Table 3 also displays results
for the three next most significant SNPs showing similar significant
associations (p-values 1.461025 to 1.161025) and Table S1 shows
results separately for each study. All three SNPs were correlated
with rs56137030 (r2$0.73 in AA and r2$0.91 in EA; Table S2).
Table 1. Distribution of study characteristics by study and overall.
Characteristics ARIC (n =3,297) GenNet (n =517) HyperGen (n=1,171) MEC (n=3,865)
Male Female Male Female Male Female Male Female
Sex 1,224 (37) 2,073 (63) 221(43) 296 (57) 391 (33) 780 (67) 1,037 (27) 2,828 (73)
Age
Mean (+/2SD) 53.8 (6.0) 53.4 (5.7) 38.2(7.1) 38.4(8.0) 47.6 (12.5) 48.0 (12.4) 61.9 (8.0) 58.6 (8.8)
Range (max-min) 44–66 44–66 22–64 20–62 21–85 20–81 45–76 45–77
Height (m)
Mean (+/2SD) 176.2 (6.7) 163.2 (6.2) 176.9(7.2) 164.3(6.4) 175.8 (7.0) 162.4(6.2) 175.0 (6.5) 161.3 (6.4)
Range (max-min) 153–197 125–188 155–196 138–183 155–198 145–183 153–198 133–198
Weight (kg)
Mean (+/2SD) 86.7 (16.5) 82.4 (17.8) 86.8(22.8) 88.8(25.2) 93.0(21.9) 89.3(22.0) 86.3 (14.3) 77.6 (16.6)
Range (max-min) 50.9–165.9 44.5–177.3 54.9–204.3 49.5–175.2 54.9–181.4 45.4–210.0 49.0–179.3 43.6–181.6
BMI (kg/m2)
Mean (+/2SD) 27.9 (4.9) 31.0 (6.5) 27.4(6.9) 32.9(9.2) 30.0(6.3) 33.7(7.6) 27.3 (4.2) 28.9 (6.0)
Range (max-min) 18.6–54.4 18.5–65.9 18.8–62.8 18.9–63.2 18.6–52.4 19.4–62.7 18.6–60.2 18.6–64.7
Obesity (BMI.=30), n (%) 360 (29) 1010 (49) 63 (29) 161 (54) 181(46) 499(64) 212 (20) 990 (35)
Characteristics WHI genotyped WHI imputed All (n = 20,488)
Female (n=5,312) Female (n=6,326) Male Female Both
Sex 5,312 (100) 6,326 (100) 2,873 (14) 17,615 (86) 20,488 (100)
Age
Mean (+/2SD) 61.2(7.2) 61.8 (7.1) 54.7 (8.0) 59.1 (7.6) 58.5 (7.7)
Range (max-min) 50–79 50–79 22–85 20–81 20–85
Height (m)
Mean (+/2SD) 162.6 (6.3) 162.4 (6.4) 175.7 (6.7) 162.4 (6.3) 164.3 (6.4)
Range (max-min) 100–192 117–194 153–198 100–198 100–198
Weight (kg)
Mean (+/2SD) 83.3 (18.4) 81.9 (17.7) 87.4 (17.2) 82.1 (18.1) 82.9 (18.0)
Range (max-min) 45.0–187.0 39–181 49.0–204.3 39–210 39.0–210
BMI (kg/m2)
Mean (+/2SD) 31.5 (6.8) 31.0 (6.4) 27.9 (5.1) 31.0 (6.6) 30.5 (6.4)
Range (max-min) 18.6–68.3 18.6–69.2 18.6–62.8 18.5–69.2 18.5–69.2
Obesity (BMI.=30), n (%) 2806 (53) 3185 (50) 816 (28) 8651 (49) 9467 (46)
doi:10.1371/journal.pgen.1003171.t001
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rs56137030 and the three next most significant SNPs are located
in intron 1 of the FTO gene, approximately in the middle of the
region (Figure 1). The nine GWAS index SNPs previous
highlighted in EA studies are also located in the same intron 1
FTO region and results for these nine GWAS index SNPs are
provided in Table 3 showing p-values,0.05 for five out of the nine
index SNPs (0.03 to 3.061024).
The most significant variant, rs56137030, was correlated at
r2.0.5 with 103 SNPs in Europeans (Figure 1a), including eight of
the nine GWAS index SNPs (Table S2). In contrast in AAs
rs56137030 was correlated with only 28 SNPs at r2.0.5 (Table
S2, Figure 1b). All 28 variants correlated with rs56137030 in AA
showed some evidence of association with BMI (p-values 0.0057 to
1.161025) and no or limited evidence of heterogeneity (all p for
heterogeneity .0.04). To investigate if any of these correlated
SNPs were associated with BMI independently from rs56137030
we adjusted each SNP for rs56137030 (including rs56137030 and
a second SNP simultaneously in one model). None of these
variants remained significant at p,0.05 (Table S2). As expected, the
p-values of rs56137030 were also less significant in these conditional
analyses, particularly for SNPs highly correlated in AA, demon-
strating that these findings are not independent. All 28 SNPs
correlated with rs56137030 (r2.0.5) in AA are located between
53,800,954 and 53,845,487, spanning a 44.5 kb region about
104.8 kb downstream of the exon 1 boundary, and ending about
1.4 Kb after exon 2 ends [no variant in exon 2 was genotyped or
imputed and, to our knowledge, only 3 variants (rs116753298,
Figure 1. Association results (p-values) and correlation structure for all SNPs in the 16q12.2/FTO region and lnBMI among African
Americans using rs56137030 to calculate correlation among SNPs (LocusZoom plots). The top half of each figure has physical position
along the x axis, and the2log10 of the meta-analysis p-value on the y-axis. Each dot on the plot represents the p-value of the association for one SNP
with lnBMI across all studies. The most significant SNP (rs56137030) is marked as a purple diamond. The color scheme represents the pairwise
correlation (r2) for the SNPs across the 16q12.2/FTO region with the most significant SNP (rs56137030). Gray squares indicate that correlation was
missing for this p-value because the variant was monomorphic in EA. The bottom half of the figure shows the position of the genes across the region.
A and B show the same region and results. The only difference between A and B is that in A correlation with the most significant SNP (rs56137030)
was calculated based on EAs, specifically based on data from 65 European Americans (Utah residents with Northern and Western European ancestry
from the CEPH collection, CEU) sequenced as part of the 1000 Genomes Project and B correlation was based on 61 African Americans from the South-
west (ASW) and sequenced as part of the 1000 Genomes Project.
doi:10.1371/journal.pgen.1003171.g001
Table 2. Distribution of allele frequency of SNPs in the FTO
fine-mapping region.
SNP n %
Allele frequencya
0.14%–1% 627 16.7%
.1%–5% 1346 35.8%
.5%–10% 431 11.5%
.10%–25% 679 18.1%
.25% 673 17.9%
Total 3756 100.0%
Exonic SNPsb
SNPs in RPGRIP1L exons 15 0.4%
synonymous SNPs in RPGRIP1L 3 0.1%
missense SNPs in RPGRIP1L 12 0.3%
SNPs in FTO exons 6 0.2%
synonymous SNPs in FTO 4 0.1%
missense SNPs in FTO 2 0.1%
aBased o allele frequency for all AA participants in this study.
bBased on data from the Exome Variation Server (http://snp.gs.washington.edu/
EVS/ accessed August 2012).
doi:10.1371/journal.pgen.1003171.t002
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rs149393601, and chr16:53844100) all with allele frequency,0.1%
have been reported in FTO exon 2 so far [36,37]].
To predict the molecular mechanisms underlying the genetic
association signals, and to identify candidate variants for functional
follow-up, rs56137030 and variants in LD (r2.0.5; n = 28) were
assessed for overlap with eleven different genome-wide functional
annotation datasets (Table S3, Material and Methods). Among
these 29 variants, six (rs11642015, rs17817497, rs3751812,
rs17817964, rs62033408, and rs1421085) were located within
candidate intronic regulatory elements, including two (rs3751812
and rs1421085) that were within highly sequence-conserved
elements among vertebrates, and two (rs11642015 and
rs1421085) that were predicted to have allele-specific binding
affinities for different transcription factors. Specifically, we
predicted that only the T allele at rs11642015 binds Paired box
protein 5 (PAX5) and that the C allele at rs1421085 has a
substantially reduced binding affinity for Cut-like homeobox 1
(CUX1; Figure S1).
Outside the known FTO intron 1 region, we observed no strong
evidence for a second independent signal: When we adjusted each
SNP for rs56137030 the most significant SNPs outside of the FTO
intron 1 region was a SNP located at position 53710931 (no rs
number reported) intronic of the neighbor gene RPGRIP1L
(conditional p-value 7.761024) followed by rs8051873 in intron
8 of FTO (conditional p-value 0.0011).
Table S4 shows results for variants highlighted in previous AA
studies. Of these nine SNPs only two SNPs had a p-values,0.05
(rs3751812, p value 0.0012).
Discussion
In this large study of over 20,000 AAs we densely fine mapped the
entire FTO gene and adjacent RPGRIP1L gene, spanning a total region
of almost 650 kb. We observed significant associations for variants in
the known locus in intron 1 of FTO. Due to reduced correlation in AA
compared with EA with the most significant SNPs, we were able to
substantially reduce the number of functional candidates. Six SNPs
were located within candidate intronic regulatory elements, including
rs1421085, for which we predicted allele-specific binding affinity for the
transcription factor CUX1. Because we did not focus solely on the
known FTO intron 1 region, we were able to comprehensively
investigate the region; however, this approach revealed no evidence for
a second independent signal in AA.
This is one of the first studies of the Metabochip in an ancestral
group that is particularly well suited for fine-mapping GWAS loci,
due to its distinct linkage disequilibrium (LD) patterns and lower
LD overall. Our example clearly shows the powerful approach of
studying a large AA population, substantially reducing the number
of possible functional variants compared with European descent
populations. While very large number of Europeans and EAs are
genotyped on the Metabochip, the number of Minority popula-
tions genotyped on this chip is substantially smaller; however, this
is the focus of the PAGE Study. As many papers using the
Metabochip in European populations will be published over the
next years, our results show the important contribution that
Minority populations and, in particularly AA, will have for
systematic mapping of GWAS loci.
The importance of the 16q12.2/FTO locus for obesity-related
traits was identified in genome-wide scans of Europeans. These
scans highlighted several variants within the FTO intron 1, all of
which, except for rs6499640, are in high LD with each other in EA
[1–7]. Consistently these studies showed an increase in BMI
(,1.1% to 1.3% per risk allele; [7]). However, AA studies showed
very limited or no evidence for an association with rs9939609
[2,5,6,14,18,28–31], rs1121980 [18,19,28,30,31], rs17817449
[18,19,28–31], or the previously reported functional variant
Table 3. Association between SNPs in the FTO region and BMI for all studies combined.
SNP Allelesb CAFc % change in BMI per coding allele nom.p Rsqd p.het
rs# Positiona Codingb Baselineb Beta estimate 95%CI
Five most significant variants (all in the FTO intron 1 region)
rs56137030 53825905 A G 0.12 1.35 (0.76,1.95) 8.3E-06 0.98 1.3E-01
rs62033400 53811788 G A 0.12 1.35 (0.76,1.95) 1.1E-05 0.99 1.3E-01
rs7188250 53834607 C T 0.12 1.34 (0.75,1.94) 1.3E-05 0.97 8.3E-02
rs62033413 53830055 G C 0.12 1.33 (0.74,1.93) 1.4E-05 0.98 4.5E-02
Index SNPs of GWAS (variants highlighted in previous studies of EA; all in FTO intron 1 region)
rs9939609 53820527 T A 0.52 0.04 (20.33,0.41) 8.2E-01 1.00 5.5E-01
rs8050136 53816275 A C 0.44 0.42 (0.03,0.82) 3.2E-02 1.00 4.9E-02
rs1421085 53800954 G A 0.12 1.11 (0.49,1.72) 3.0E-04 1.00 2.6E-01
rs17817449 53813367 C A 0.39 0.37 (20.02,0.77) 5.9E-02 1.00 5.6E-02
rs1121980 53809247 A G 0.47 0.35 (20.02,0.73) 7.2E-02 1.00 2.4E-01
rs1558902 53803574 T A 0.12 1.13 (0.46,1.80) 1.0E-03 1.00 2.4E-01
rs6499640 53769677 A G 0.65 0.05 (20.34,0.44) 8.1E-01 1.00 1.6E-01
rs9930506 53830465 G A 0.22 0.66 (0.19,1.14) 5.5E-03 1.00 1.6E-01
rs9941349 53825488 A G 0.12 0.69 (0.20,1.19) 5.4E-03 1.00 5.7E-01
aSNPposition based on build 37.
bCoding = coding allele, Base =baseline allele (risk estimates provide the log additive effect per copy of the coding allele).
cCAF= coding allele frequency.
dRsq =measurement of imputation accuracy, ranging from 0 (low) to 1 (high).
doi:10.1371/journal.pgen.1003171.t003
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rs8050136 [2,6,19,27–29,31,32]. We observed nominal evidence
for association with BMI for rs17817449 and rs8050136, but
results were not among the most significant associations.
rs1421085 was significantly associated in our study
(p = 361024;Table S2) and was also found to be associated in
the study from Nock et al. [29] (n = 469, p-value = 761024),
Hassanein et al. [31] (n = 4,217, p-value = 361024), and Hester et
al. [32] (n = 4,992, p-value = 0.07) but not with four smaller AA
studies (#1000 AA subjects) [5,18,28,38]. Consistent with our
finding Hassanein et al. [31] also observed a significant association
with rs9941349 and rs1558902 (n = 9,881, p-value = 461026 and
n=4,217, p-value = 261025, respectively), these SNPs have not
been genotyped in other AA studies. However, to put these
findings into context with other variants in this region a
comprehensive evaluation of all variants is needed.
To conduct a more comprehensive evaluation of the FTO locus,
some AA studies extended the SNPs list from the EA index SNPs
described above (Table S4). Grant et al. [27] analyzed eleven FTO
SNPs genotyped as part of their GWAS in about 2,000 AA
children and only rs3751812 showed a marginally significant
association with BMI (p-value = 0.02). Wing et al. [18,19]
genotyped up to 27 SNPs in the intron 1 of FTO in a cohort
study and family study including 288 and 604 AA, respectively,
and observed an association of BMI with rs1108102 (p-
value = 561024; [18]); however, this finding was not confirmed
in their cohort study or in our larger meta-analysis (Table S4). A
fine mapping study of 47 tagging SNPs in 497 AA children [28]
identified an association of rs8057044 (p-value = 561024) with
BMI, which was not replicated by the current study. In two fine-
mapping studies [5,14], no FTO-BMI associations were noted,
possibly because the majority of subjects were lean (,75% had a
BMI between 18–25) in one study [14], or because the sample size
was small in both studies (about 1,100). Hassanein et al. [31]
genotyped 34 tagging SNPs in the FTO intron 1 region in 4,217
AA and followed up findings from two variants (rs3751812, p-
value = 461024 and rs9941349, p-value = 661025) in four addi-
tional studies (n = 5,664), adding some support (p-values ranging
from 0.016 to 0.64) which resulted in overall p-values of 2.661026
and 3.661026, respectively. The authors concluded that this
finding reduced the potential functional variants to those
correlated with these two variants. Both variants (rs3751812 and
rs9941349) were also associated in our meta-analysis (p-value
0.001 and 0.005, respectively; Table S4), although they were not
among the most significant findings. In summary, except for
Hassanein et al. [31], studies in AA were relatively small and
showed mixed results that were mainly not replicated in our study.
As the number of variants genotyped in any AA study was limited
(10 to 50 SNPs), we were able to investigate if genotyping or
imputing additional variants in this region (in total 3,756) may
even further reduce the list of possible functional variants and
search for second independent signal(s).
In our analysis, rs56137030 was most significantly associated
with BMI. In EA, rs56137030 has a similarly high allele frequecy
as the previously reported GWAS index SNPs (A allele frequen-
cy = 0.42) and was highly correlated with the GWAS index SNPs
(r2$0.87), except for rs6499640 (r2 = 0.12), which is also not
strongly correlated with any of the other GWAS index SNPs in EA
or AA. In AA, the correlation between rs56137030 and GWAS
index SNPs varied substantially (r2 = 0.001 to 0.73), demonstrating
that studying AA can substantially reduce the bin of correlated
SNPs defined by the index signal identified in EA. Specifically, the
number of SNPs correlated with rs56137030 at r2.0.5 was 103 in
EA, but only 28 in AA. Including these 28 SNPs together with
rs56137030 in conditional analyses showed that the significance of
each of the SNPs, as well as rs56137030, was substantially
reduced, supporting the idea that any of the highly correlated
SNPs is a potential functional candidate. rs56137030 and all 28
highly correlated SNPs are non-coding, suggesting that the
functional variant is likely to have a cis-regulatory effect. Among
these variants, six are located within the candidate intronic
regulatory elements, two of which are highly conserved, and two
that are predicted to confer allele-specific binding affinities for
transcription factors. The variant rs1421085 is within a highly
conserved element and may be particularly interesting, because
the C allele has a substantially reduced binding affinity for CUX1,
which has been previously implicated in the transcriptional
regulation of FTO [34]. Accordingly, this variant is a compelling
candidate for follow-up functional evaluation, though outside the
scope of the present study.
We did not observe any evidence for a second independent
signal within the broader 16q12.2/FTO region. This finding is
consistent with the only other AA study that extended the fine-
mapping approach beyond intron 1 to the entire FTO gene
including 262 tagSNPs in 1,485 subjects [30]. However, even
within our substantially larger study of over 20,000 AAs, power to
identify second independent signals may still have been limited,
particularly for less frequent variants or variants with weaker
effects, given the increased burden of multiple comparisons that
needs to be adjusted for when testing all SNPs across the entire
region.
Several limitations warrant consideration to inform fine-
mapping and functional characterization studies. To comprehen-
sively evaluate the region we not only included directly genotyped
SNPs, which included all SNPs known at the time of the chip
development and suitable for genotyping SNPs but we also
imputed to the most recent version of the 1000 Genomes Project.
While this approach provides a rather complete list of variants
imputed SNPs ted to be called with varying accuracy. To account
for the imputation accuracy we used the dosage, which we showed
results in unbiased estimates [39]. However, we also note that the
overall p-value of a SNP is impacted by the imputation accuracy
(lower imputation accuracy results in higher p-values). According-
ly, it is important for the interpretation of the results that not only
the most significant SNPs will be considered as functional variants
but also those correlated with the most significant SNPs as done in
this paper. Second, for a part of the WHI samples directly
genotyped SNPs were only available from a smaller subset of SNPs
as genotyping in this subset was based on a GWAS platform and
not the dense Metabochip. However, the imputation Rsq as a
measurement of the accuracy was very high (Table S1). Third,
despite the relative large samples size of over 20,000 AA the
statistical significance of the finding is relative weak compared to
previous studies in European descent populations for the FTO
region. We note that the relative weak power of our study is not
due to differences in the observed effect size, e.g. we observed a
1.35% change in BMI per allele for the most significant SNP while
the replication stage of Willer et al. [7] observed a 1.25% change
in BMI per allele of their most significant FTO SNP (rs9939609).
However, the substantially lower allele frequency in AA compared
with EA (12% vs. 41%) and the larger variance of BMI in AA
populations (e.g. the standard deviation in our study was 6.4 kg/
m2 compared with 4.2 kg/m2 in European populations [7]
explains the reduce power. Fourth, our functional characterization
is based on in silico analyses and requires experimental validation.
Finally, the majority of study participants were female and it is
unclear how a predominantly female population may have
influenced the results.
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To our knowledge, this is the largest and most comprehensive
fine-mapping study conducted to date in AA. Our findings likely
rules out that several of the EA index SNPs in intron 1 of FTO
such as rs9939609, as well as a large fraction of SNPs correlated in
EA but not in AA are the underlying functional variants. With
rs56137030 and its correlated SNPs, our finding points us closer to
the functional variant(s). Among these, rs1421085 is the most
compelling candidate for follow-up functional evaluation. Impor-
tantly, our study demonstrated that comprehensive fine-mapping
in AA provides a powerful approach to narrow in on the
functional candidate(s) underlying the initial GWAS findings in
EA.
Materials and Methods
Ethics statement
All studies were approved by Institutional Review Boards at
their respective sites, and all participants provided informed
consent.
Study populations
PAGE involves several studies, described briefly below and in
more detail in Text S1 as well as at the PAGE website (https://
www.pagestudy.org) [40]. In brief, participants were recruited
from Atherosclerosis Risk in Communities Study (ARIC), GenNet,
Hypertension Genetic Epidemiology Network (HyperGEN),
Multiethnic Cohort (MEC), and Women’s Health Study (WHI).
ARIC randomly selected and recruited 15,792 participants aged
45–64 at four U.S. communities [41]. GenNet and HyperGEN are
two family-based studies designed to investigate the genetics of
hypertension and related conditions [42]. The Multiethnic Cohort
(MEC) is a population-based prospective cohort study of over
215,000 men and women in Hawaii and California aged 45–75 at
baseline (1993–1996) and primarily of five ancestries [43]. The
WHI encompasses four randomized clinical trials as well as a
prospective cohort study of 161,808 post-menopausal women aged
50–79, recruited (1993–1998) and followed up at 40 centers across
the US [44]. All studies collected self-identified racial/ethnic
group via questionnaire. We selected all AA participants from
ARIC, HyperGEN, and GenNet for genotyping. In MEC, a
subset of AAs was selected based on availability of biomarker or as
controls for nested case-control studies. WHI included all AAs who
provided consent for DNA analysis. We excluded underweight
(BMI,18.5 kg/m2) and extremely overweight (BMI.70 kg/m2)
individuals with the assumption that these extremes could be
attributable to data coding errors, an underlying illness or possibly
to a familial syndrome and hence, a rare mutation. We also limited
analysis to adults defined as age .20 years.
Anthropometric measurements
For ARIC HyperGEN, GenNet and WHI, BMI was calculated
from height and weight measured at time of study enrollment. In
MEC, self-reported height and weight were used to calculate
baseline BMI. A validation study within MEC has shown high
validity of self-reported height and weight. Specifically this study
showed that BMI was under-estimated based on self-reported
compared to measured weight, but the difference was small (,1
BMI unit) and comparable to the findings from national surveys
[45].
SNP selection for genotyping
SNPs were included as part of the Metabochip, a 200 k Illumina
customized iSelect array developed through the collaborative
efforts of several consortia working on metabolic syndrome related
diseases. Details on the design can be found elsewhere (http://
www.sph.umich.edu/csg/kang/MetaboChip/). In brief, SNPs
within the 16q12.2/FTO region were selected based on 1000
Genomes Pilot 1 and HapMap phase 2. The boundaries around
each GWAS index SNP were determined by identifying all SNPs
with r2$0.5 with the index SNP, and then expanding the initial
boundaries by 0.02 cM in either direction using the HapMap-
based genetic map [46]. The total interval size of the 16q12.2/
FTO region was 646 kb. All 1000 Genomes Pilot 1 SNPs obtained
from Sanger Institute (August 12, 2009) and the Broad Institute
(August 11, 2009) were considered as potential fine mapping
SNPs, unless SNP allele frequency was,0.01 in all three HapMap
samples (CEU, YRI and HBC/JPT). SNPs were excluded if (a) the
Illumina design score was ,0.5 or (b) there were SNPs within
15 bp in both directions of the SNP of interest with allele
frequency of .0.02 among Europeans (CEU). SNPs annotated as
nonsynonymous, essential splice site, or stop codon were included
regardless of allele frequency, design score, or nearby SNPs in the
primer.
Genotyping and quality control
Samples were genotyped on the Metabochip at the Human
Genetics Center of the University of Texas-Houston (ARIC,
GenNet and HyperGEN), the University of Southern California
Epigenome Center (MEC), and the Translational Genomics
Research Institute (WHI). Each center also genotyped 90
HapMap YRI (Yoruba in Ibadan, Nigeria) samples to facilitate
cross-study quality control (QC), as well as 2–3% study-specific
blinded replicates to assess genotyping reproducibility. Genotypes
were called separately for each study using GenomeStudio with
the GenCall 2.0 algorithm. Samples were called using study-
specific cluster definitions (based on samples with call rate .95%,
ARIC, MEC, WHI) or cluster definitions provided by Illumina
(GenNet, HyperGEN) and kept in the analysis if call rate was
.95%. We excluded SNPs with GenTrain score ,0.6 (ARIC,
MEC, WHI) or ,0.7 (GenNet, HyperGEN), cluster separation
score ,0.4, call rate ,0.95, and Hardy-Weinberg Equilibrium
p,161026. We also excluded SNPs based on Mendelian errors in
30 YRI trios .1, replication errors .2 with discordant calls (when
comparing across studies) in 90 YRI samples .3, and discordant
calls for 90 YRI genotyped in PAGE versus HapMap database
.3. In total, we successfully genotyped 1,694 out of 1,818 variants
in the 16q12.2/FTO region. After excluding 165 SNPs that were
monomorphic or had very low allele frequency (,0.01%) we
included 1,529 variants in the analysis.
For ARIC, MEC and WHI we identified related persons using
PLINK by estimating identical-by-descent (IBD) statistics for all
pairs. When apparent first-degree relative pairs were identified, we
excluded from each pair the member with the lower call rate. We
excluded from further analysis samples with an inbreeding
coefficient (F) above 0.15 (ARIC, MEC, WHI) [47]. We
determined principal components of ancestry in each study
separately using EIGENSOFT [48,49] and excluded apparent
ancestral outliers from further analysis as described elsewhere [50].
In total 240 subjects failed genotyping (ARIC=27, GenNet = 9,
HyperGEN=26, MEC=140, and WHI= 27). After further
excluding subjects based on age and BMI (see above), a total of
14,162 subjects with Metabochip data were included (3,297 from
ARIC, 517 from GenNet, 1,171 from HyperGEN, 3,865 from
MEC, and 5,312 from WHI). In addition we included 6,326 WHI
participants genotyped as part of the SNP Health Association
Resource (SHARe) on the Affymetrix 6.0 platform. Details can be
found elsewhere [51].
Fine-Mapping of FTO Locus in African Americans
PLOS Genetics | www.plosgenetics.org 7 January 2013 | Volume 9 | Issue 1 | e1003171
Imputation to 1000 Genomes Project
To impute to the 1000 Genomes Project we used as the
reference panel the haplotypes of the 1092 samples (all popula-
tions) from release version 2 of the 1000 Genomes Project Phase I
(ftp://ftp-trace.ncbi.nih.gov/1000genomes/ftp/release/20110521)
[52]. Combining reference data from all populations has been
found to improve imputation accuracy of the low-frequency
variants [53], and, hence, is recommended. We built the target
panel by combining all genotype data in the FTO region from all
studies. We used genotyped data from the Metabochip for all
studies, except for WHI SNP Health Association Resource
(SHARe, n= 6,326 samples) where we used genotype data from
the Affymetrix 6.0 platform. The target panel was phased using
Beagle [54]. We then performed a haplotype-to-haplotype
imputation to estimate genotypes (as allele dosages) at 1000
Genomes Project variants. The phased target panel was imputed
to the interval 53.5–54.2 Mb on chromosome 16 of the 1000
genomes reference panel using minimac [55]. To evaluate the
quality of each imputed SNP we calculated Rsq. We excluded
imputed SNPs with Rsq,0.9 for SNPs with allele frequency
,0.5%, Rsq,0.8 for SNPs with allele frequency .0.5–1%,
Rsq,0.7 for SNPs with allele frequency .1–3%, Rsq,0.6 for
SNPs with allele frequency .3–5%, and Rsq,0.5 for SNPs with
allele frequency.5%. Given the large reference panel this resulted
in high imputation quality [51]. To calculate pairwise correlation
between variants we used the 1000 Genomes Project data,
specifically we used 61 African Americans from the South-west
(ASW) and 65 European Americans (Utah residents with Northern
and Western European ancestry from the CEPH collection, CEU).
Statistical analysis
The association between each SNP and natural log-transformed
BMI (lnBMI) was estimated using linear regression. SNP
genotypes were coded assuming an additive genetic model (i.e.,
0, 1, or 2 copies of the coded allele). All analyses were adjusted for
age (continuous), sex, and study site (as applicable). All models
(except WHI) included sex*age interaction terms to account for
possible effect modification by sex. In addition, we adjusted for the
top two principal components of ancestry. Family data from
GenNet and HyperGEN was analyzed using mixed models
(variance component models) to account for relatedness.
Results (b and SEs for lnBMI) were combined with fixed-effects
meta-analysis weighting the effect size estimates (b-coefficients) by
their estimated standard errors, using METAL [56]. We evaluated
Q-statistic and I2 as a measure of heterogeneity [57,58], to
describe the presence or absence of excess variation between the
PAGE cohorts. For ease of interpretation, we calculated the %
change in BMI per copy of the effect allele based on the beta for
the lnBMI. To graphically display the results, we used LocusZoom
[59]. We tested for independence of findings by including the most
significant variant and each of the other variant into the same
model (i.e. we included 2 variants simultaneously in one model).
We evaluated if SNPs are independent by investigating the
p-value. For an independent SNP the p-value would remain low/
similar after adjusted for the most significant SNP.
Bioinformatics
We conducted a bioinformatic characterization for the most
significant SNP and all SNPs correlated with the most sigificant
SNP (r2.0.5). We implemented in-house Perl scripts to query
bioinformatic databases, and assigned each of the 16 SNPs to one
or more of the functional annotation datasets listed in Table S3.
These datasets are not mutually exclusive. For example, a SNP
can be located within both a candidate regulatory element (dataset
#7) and a CTCF binding site (dataset #10). Because FTO is
expressed and may have functional relevance in a wide array of
tissues, we defined candidate cis-regulatory elements (dataset #7)
as DNaseI hypersensitive sites (open chromatin loci) that are
present in at least one human cell type. For SNPs that occur within
predicted transcription factor binding sites (datasets #3 and #8),
we computed transcription factor binding affinity for each SNP
allele using the PWM-scan algorithm [60], as described previously
[61].
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